Study Description
This is Phase Ib/II, multicenter, open-label adaptive platform study of JDQ443 with select therapies in patients with advanced solid tumors harboring the KRAS G12C mutation.
JDQ443 will be considered "backbone" treatment in this trial and combined with selected therapies, or "partner(s)". The combination of a backbone and a partner will constitute a treatment arm. After dose escalation, treatment arms that reach a maximum tolerated dose /recommended dose and are determined to be safe may, but are not required to, proceed to Phase II to further explore safety, tolerability, and anti-tumor activity.
Interventions
cetuximab
JDQ443
Ribociclib
trametinib
Eligibility Criteria
Inclusion Criteria:
Dose Escalation:
- Patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors who have received standard of care therapy or are ineligible to receive such therapy.
Phase II:
Patients with advanced (metastatic or unresectable) KRAS G12C mutant non-small cell lung cancer who have received platinum-based chemotherapy regimen and immune checkpoint inhibitor therapy, unless patient was ineligible to receive such therapy
Patients with advanced (metastatic or unresectable) KRAS G12C mutant colorectal cancer who have received fluropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, unless patient was ineligible to such therapy.
All patients:
ECOG performance status of 0 or 1.
Patients must have a site of disease amenable to biopsy and be a candidate for tumor biopsy according to the treating institution's guidelines.
Exclusion Criteria:
Tumors harboring driver mutations that have approved targeted therapies, with the exception of KRAS G12C mutations
Prior treatment with a KRAS G12C inhibitor is excluded for patients in a subset of groups in Phase II.
Active brain metastases, including symptomatic brain metastases or known leptomeningeal disease
Clinically significant cardiac disease or risk factors at screening
Insufficient bone marrow, hepatic or renal function at screening Other protocol-defined inclusion/exclusion criteria may apply
Study Location
Novartis Investigative Site
Recruiting
Leuven,3000,Belgium
Novartis Investigative Site
Recruiting
Lyon,69373,France
Novartis Investigative Site
Recruiting
Bordeaux,33076,France
Novartis Investigative Site
Recruiting
Freiburg,79106,Germany
Novartis Investigative Site
Recruiting
Ulm,89081,Germany
Novartis Investigative Site
Recruiting
Milano,MI,20162,Italy
Novartis Investigative Site
Recruiting
Seoul,03080,Korea, Republic of
Novartis Investigative Site
Recruiting
Singapore,168583,Singapore
Novartis Investigative Site
Recruiting
Madrid,28034,Spain
Novartis Investigative Site
Recruiting
Madrid,28050,Spain
Novartis Investigative Site
Recruiting
Barcelona,Catalunya,08036,Spain
Dana Farber Cancer Institute Dept.of DFCI
Recruiting
Boston,Brian Schwalm email: [email protected] -- Jia Luo,02215 - Massachusetts,United States
NYU School of Medicine Langone Health
Recruiting
New York,Sasha Richardson (212-731-5662) email: [email protected] -- Janice Mehnert,10015 - New York,United States
Massachusetts General Hospital .
Recruiting
Boston,Aaron Paul Doss email: [email protected] -- Rebecca Heist,02114 - Massachusetts,United States
Worldwide Contacts
If the location of your choosing does not feature any contact detail, please reach out using the information below.